Tag: CAPA

Case Studies: Under-Reporting of Deviations and Regulatory Consequences Case Studies: Under-Reporting of Deviations and Regulatory Consequences Clinical trials are pivotal in the development of new therapies, and protocol deviations can significantly impact the integrity and outcomes of these studies. Under-reporting of these deviations poses regulatory challenges, leading to consequences that affect clinical trial operations. This…

Read More “Case Studies: Under-Reporting of Deviations and Regulatory Consequences” »

Timelines and Content Requirements for Serious Breach Notifications In the evolving landscape of clinical trials, particularly biosimilar clinical trials, maintaining compliance with regulatory frameworks is paramount. Serious breaches, or deviations from established protocols and guidelines, can significantly impact the integrity of clinical research outcomes and the safety of participants. This article serves as a comprehensive…

Read More “Timelines and Content Requirements for Serious Breach Notifications” »

Aligning Sponsor, CRO and Site SOPs on Deviation Reporting to Regulators Aligning Sponsor, CRO and Site SOPs on Deviation Reporting to Regulators In the landscape of clinical trials, effectively navigating regulatory requirements is crucial for sponsors, Contract Research Organizations (CROs), and clinical trial sites. One of the most critical aspects of clinical trial management revolves…

Read More “Aligning Sponsor, CRO and Site SOPs on Deviation Reporting to Regulators” »

IRB/IEC Reporting Thresholds for Deviations That Impact Safety or Rights IRB/IEC Reporting Thresholds for Deviations That Impact Safety or Rights Introduction to IRB/IEC Reporting in Clinical Trials In clinical research, oversight by institutional review boards (IRBs) or ethics committees (IECs) is paramount for protecting the rights and welfare of participants. This article aims to provide…

Read More “IRB/IEC Reporting Thresholds for Deviations That Impact Safety or Rights” »

Coordinating Notifications Across FDA, EMA, MHRA and Local Ethics Bodies In the complex landscape of clinical trials, ensuring compliance with various regulatory bodies is critical for maintaining the integrity and success of a study. This article provides a detailed, step-by-step tutorial for clinical operations, regulatory affairs, and medical affairs professionals on coordinating notifications across the…

Read More “Coordinating Notifications Across FDA, EMA, MHRA and Local Ethics Bodies” »

Regulatory Notifications and IRB Reporting for Serious Protocol Non-Compliance Regulatory Notifications and IRB Reporting for Serious Protocol Non-Compliance Introduction to Protocol Non-Compliance in Clinical Trials Protocol non-compliance refers to instances when a clinical trial diverges from its approved protocol. This issue is critical, particularly in clinical trials involving medications for diseases such as ankylosing spondylitis,…

Read More “Regulatory Notifications and IRB Reporting for Serious Protocol Non-Compliance” »

When Does a Protocol Deviation Become a Reportable Serious Breach? In the realm of clinical research, adherence to the study protocol is crucial for the integrity of data and the well-being of participants. Understanding when a protocol deviation escalates to a reportable serious breach requires knowledge of regulatory frameworks and guidelines. This article serves as…

Read More “When Does a Protocol Deviation Become a Reportable Serious Breach?” »